CLVS

Clovis OncologyNasdaqGS:CLVS Stock Report

Market Cap

US$573.1m

7D

11.0%

1Y

-30.5%

Updated

18 Sep, 2021

Data

Company Financials +
CLVS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

CLVS Overview

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.

Clovis Oncology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clovis Oncology
Historical stock prices
Current Share PriceUS$4.84
52 Week HighUS$4.06
52 Week LowUS$11.10
Beta1.7
1 Month Change12.56%
3 Month Change-18.93%
1 Year Change-30.51%
3 Year Change-85.05%
5 Year Change-86.97%
Change since IPO-61.47%

Recent News & Updates

Jul 30

Clovis: Compelling With Upcoming Catalysts

After a 25% selloff in the last 6 weeks, Clovis presents a compelling risk/reward ratio with upcoming catalysts in the next 3 months. Athena data is due in September which could move Rubraca into the largest oncology market in its class and make it a potential blockbuster. Targeted radiotherapy is the future of cancer treatment and Clovis is a pioneer in this area with its FAP pipeline. Earnings on August 4 will provide much-needed clarity from management.

Shareholder Returns

CLVSUS BiotechsUS Market
7D11.0%0.3%-0.6%
1Y-30.5%25.7%33.8%

Return vs Industry: CLVS underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: CLVS underperformed the US Market which returned 33.6% over the past year.

Price Volatility

Is CLVS's price volatile compared to industry and market?
CLVS volatility
CLVS Beta1.7
Industry Beta1.03
Market Beta1

Stable Share Price: CLVS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CLVS's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009429Patrick Mahaffyhttps://www.clovisoncology.com

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.

Clovis Oncology Fundamentals Summary

How do Clovis Oncology's earnings and revenue compare to its market cap?
CLVS fundamental statistics
Market CapUS$573.10m
Earnings (TTM)-US$310.36m
Revenue (TTM)US$156.94m

3.7x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLVS income statement (TTM)
RevenueUS$156.94m
Cost of RevenueUS$34.47m
Gross ProfitUS$122.47m
ExpensesUS$432.83m
Earnings-US$310.36m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.12
Gross Margin78.03%
Net Profit Margin-197.75%
Debt/Equity Ratio-312.8%

How did CLVS perform over the long term?

See historical performance and comparison

Valuation

Is Clovis Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLVS ($4.84) is trading below our estimate of fair value ($47.25)

Significantly Below Fair Value: CLVS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLVS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CLVS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLVS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLVS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Future Growth

How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

44.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLVS's revenue (29.7% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: CLVS's revenue (29.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CLVS is forecast to be unprofitable in 3 years.


Past Performance

How has Clovis Oncology performed over the past 5 years?

0.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CLVS is currently unprofitable.

Growing Profit Margin: CLVS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CLVS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Clovis Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLVS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CLVS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Clovis Oncology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Patrick Mahaffy (58 yo)

12.42yrs

Tenure

US$3,229,519

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD3.23M) is above average for companies of similar size in the US market ($USD1.68M).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLVS's management team is seasoned and experienced (5.7 years average tenure).


Board Members

Experienced Board: CLVS's board of directors are seasoned and experienced ( 12.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CLVS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.


Top Shareholders

Company Information

Clovis Oncology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: CLVS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$573.103m
  • Shares outstanding: 118.41m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 00:52
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.